Proactive Investors - Run By Investors For Investors

Allergy Therapeutics' Murray Skinner talks up 'huge market opportunities' for dust mite treatment

Allergy Therapeutics plc (LON:AGY) chief scientific officer Murray Skinner speaks to Proactive about their phase I clinical study of Acarovac MPL receiving official sign-off in Spain.

A total of 32 patients will receive Acarovac, which will be administered at two different doses. The trial is expected to take 12 months from start to finish.

Meet Gold Road Resources Ltd, Cellmid Ltd, Gold Road Resources Ltd, Altech Chemicals Ltd and Silver City Minerals Ltd at our event, Sydney, 03 October 2017. Register here »
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use